Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764632 | 0.98 | CA14 (0.46) | CA14TDP1SSTR4HDAC1HDAC2 | |
| SCHEMBL1761184 | 0.89 | SSTR4 (0.40) | CA14TDP1SSTR4HDAC1HDAC2 | |
| SCHEMBL567647 | 0.85 | CA14 (0.45) | CA14TDP1SSTR4HDAC1HDAC2 | |
| SCHEMBL567649 | 0.85 | CA14 (0.45) | CA14TDP1SSTR4HDAC1HDAC2 | |
| SCHEMBL1764627 | 0.84 | CA14 (0.41) | CA14HDAC1HDAC2HDAC6CA12 | |
| SCHEMBL1764999 | 0.82 | CA14 (0.39) | CA14HDAC1HDAC2HDAC6CA12 | |
| SCHEMBL4574540 | 0.82 | CA14 (0.53) | CA14TDP1SSTR4HDAC1HDAC2 | |
| SCHEMBL8627528 | 0.82 | CA14 (0.59) | CA14TDP1SSTR4HDAC1HDAC2 | |
| SCHEMBL10420506 | 0.82 | CA14 (0.59) | CA14TDP1SSTR4HDAC1HDAC2 | |
| SCHEMBL25797677 | 0.82 | CA14 (0.59) | CA14TDP1SSTR4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518966-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110124677-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-7902221-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124677-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRL1, OPRK1 | CA14 4199/4885TDP1 4606/4885SSTR4 239/4885 |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | CA14 4194/4885TDP1 4656/4885SSTR4 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.